What question did this study set out to answer?

This analysis aims to evaluate the efficacy and safety of HWK-206, a novel SEZ6-targeting antibody-drug conjugate.

April 5, 2026

Abstract 4440: Preclinical assessment of HWK-206, a next-generation, biparatopic, SEZ6-targeting ADC with novel bioconjugation and linker-payload technology

Key Points

This analysis aims to evaluate the efficacy and safety of HWK-206, a novel SEZ6-targeting antibody-drug conjugate.
Investigated the mechanism of action in preclinical SCLC models.
Compared binding affinity and internalization of HWK-206 with parental antibodies.
Assessed antitumor efficacy in SCLC xenograft models.
Evaluated pharmacokinetic and safety profiles in nonclinical studies.
HWK-206 exhibited higher binding affinity to SEZ6 than existing therapies.
Induced significant DNA damage and reduced tumor cell viability.
Showed potent antitumor activity with tumor regression at doses as low as 2 mg/kg.
Demonstrated a favorable pharmacokinetic profile and good tolerability in nonclinical toxicology.

Abstract

Abstract Seizure-related 6 homolog (SEZ6) is a cell-surface transmembrane protein that plays a role in neuronal development. SEZ6 expression is highly elevated in neuroendocrine (NE) tumors, including, but not limited to, small cell lung cancer (SCLC), brain or central nervous system cancers, and NE tumors of prostate and bladder origin, and has limited expression in normal tissues. In SCLC, SEZ6 expression is correlated with worse survival outcomes. Single-epitope, SEZ6-directed antibody-drug conjugates (ADCs), such as ABBV-706, have shown initial promise in SCLC and NE neoplasms, but with some potential challenges attributed to side effects associated with these agents. HWK-206 is a next-generation ADC that utilizes a biparatopic antibody (bpAb) approach to target SEZ6, with an Fc effector-attenuated IgG1 antibody conjugated to the novel DNA topoisomerase I inhibitor, CPT116. HWK-206 was designed using novel bioconjugation (carbon bridge cysteine re-pairing) and advanced linker-payload technologies to maximize intracellular delivery while minimizing systemic exposure of free payload. The mechanism of action of the HWK-206 bpAb was investigated in preclinical SCLC models. Results showed that the HWK-206 bpAb bound to SEZ6 with higher affinity than the parental antibodies or that reported previously for ABBV-706. HWK-206 induced DNA damage and loss of SCLC tumor cell viability. Furthermore, the HWK-206 bpAb demonstrated superior binding, receptor-mediated internalization, and reduction in viability of SCLC tumor cells expressing varying levels of SEZ6, compared with the parental antibodies and historical benchmarks. Potent antitumor activity was observed in various SCLC xenograft tumor models, with tumor regression observed at single doses as low as 2 mg/kg. HWK-206 demonstrated a bystander killing effect in vitro, suggesting the ability to elicit activity against heterogeneous tumors. The pharmacokinetic (PK) and safety profiles of HWK-206 were evaluated in nonclinical toxicology studies. HWK-206 demonstrated a favorable PK profile and was well tolerated. In summary, HWK-206 is a highly potent and selective next-generation, biparatopic, SEZ6-targeted ADC that warrants further investigation. A planned phase I dose-escalation study will investigate HWK-206 in patients with advanced solid tumors. Citation Format: Kathy S. Keegan, Shihe Hou, Ashwini B. Pai, Enrico Bellomo, Erik Kratzer, Victor Peykov, Bryan Ball, Lei Wu, Mengmeng Sun, Lu Jiang, Jijie Gu, David J. Lennon, David Dornan. Preclinical assessment of HWK-206, a next-generation, biparatopic, SEZ6-targeting ADC with novel bioconjugation and linker-payload technology abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4440.

Perguntar à IA

Bookmark